Huntington's Disease

News Huntington's Disease

• Pitt team finds melatonin delays ALS symptom onset and death in mice

  Melatonin injections delayed symptom onset and reduced mortality in a mouse model of the neurodegenerative condition amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, according to a new study by researchers at the University of Pittsburgh School of Medicine. In a report published online more

• Using human brain cells to make mice smarter

  What happens when human brain cells that surround and support neurons are implanted into the brains of newborn mice? Researchers recently found that such mice had enhanced learning and memory when compared with normal mice that hadn't received the transplanted human cells. The findings indicate that more

• uniQure licenses RNA interference technology to advance Huntington’s disease program

  uniQure B.V. announced a non-exclusive cross-licensing agreement with Benitec Biopharma Ltd. giving uniQure access to Benitec’s proprietary DNA-directed RNA interference (ddRNAi) technology in Huntington’s disease. In return, uniQure granted Benitec non-exclusive access to the Company’s AAV5 deliver more

Publications Huntington's Disease

• A critical role of astrocyte-mediated nuclear factor-{kappa}B-dependent inflammation in Huntington's disease

  Huntington's disease (HD) is an autosomal disease caused by a CAG repeat expansion in the huntingtin (HTT) gene. The resultant mutant HTT protein (mHTT) forms aggregates in various types of cells, including neurons and glial cells and preferentially affects brain function. We found that two HD mous more

• The potential of carbon‐11 and fluorine‐18 chemistry: illustration through the development of positron emission tomography radioligands targeting the translocator protein 18 kDa

  The TSPO (translocator protein), also known as the peripheral benzodiazepine receptor, is upregulated in the brain of subjects suffering from neurodegenerative disorders such as Alzheimer's, Parkinson's and Huntington's disease. Moreover, this overexpression has been proved to be linked to microgl more

• Decreased expression of GLT‐1 in the R6/2 model of Huntington's disease does not worsen disease progression

  Abstract Excitotoxicity is thought to be important in the pathogenesis of Huntington's disease (HD). Glutamate is the predominant excitatory neurotransmitter in the brain, and excess activation of glutamate receptors can cause neuronal dysfunction and death. Glutamate transporters regulate the e more

Market studies Huntington's Disease

• Huntington's Disease – Pipeline Review, H2 2012

  Introduction Global Markets Direct’s, 'Huntington's Disease - Pipeline Review, H2 2012', provides an overview of the Huntington's Disease therapeutic pipeline. This report provides information on the therapeutic development for Huntington's Disease, complete with latest updates, and special featur more

• Huntington's Disease – Pipeline Review, H1 2012

  Introduction Global Markets Direct’s, 'Huntington's Disease - Pipeline Review, H1 2012', provides an overview of the Huntington's Disease therapeutic pipeline. This report provides information on the therapeutic development for Huntington's Disease, complete with latest updates, and special featur more

• Repligen Corporation (RGEN) - Financial and Strategic SWOT Analysis Review

  Repligen Corporation (Repligen) is a publicly held research focused bio pharmaceutical company engaged in development of innovative therapeutics for neurological disorders. Repligen offers recombinant protein A, immobilized protein A and protein A ELISA kits under its marketed product portfolio. In more

Websites Huntington's Disease